Small-Molecule Retinal Therapy for Multi-Pathway Angiogenesis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal vascular diseases, such as wet age-related macular degeneration and diabetic retinopathy, face challenges with high complication rates and limited efficacy from intravitreal injections of macromolecular VEGF inhibitors, necessitating a more effective and safer therapeutic approach.
Innovation Solution
A combination of at least two small molecule inhibitors (SMIs) targeting different signaling pathways, including CCR2, MCP-1, RAGE, and Rac-1, is administered to inhibit key proteins associated with retinal diseases, formulated for synergistic effect and controlled delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravitreal injections of macromolecular VEGF inhibitors are used, then retinal vascular diseases can be treated, but complication rates increase and efficacy is limited
Solution Approach 1:
The patent changes the molecular weight parameter of the inhibitors from macromolecular to small molecule, and combines multiple inhibitors targeting different signaling pathways. This parameter change improves treatment efficacy while reducing complications by avoiding the limitations of single macromolecular agents
Solution Approach 2:
The patent creates a composite therapeutic approach by combining at least two small molecule inhibitors that target different signaling pathways (VEGF, RAGE, Rac1, CCR2, MCP-1). This composite strategy addresses the limitation of single-agent therapy by simultaneously blocking multiple angiogenic pathways, thereby improving efficacy and reducing complications
2Reliability
If single pathway inhibition is used, then treatment is simple, but efficacy is limited
Solution Approach 1:
The patent merges multiple inhibition strategies by combining at least two small molecule inhibitors targeting different signaling pathways. This combination approach overcomes the efficacy limitation of single pathway inhibition while maintaining manageable treatment complexity through coordinated delivery
Solution Approach 2:
The patent creates a multi-functional treatment regimen where small molecule inhibitors simultaneously block multiple angiogenic pathways (VEGF, RAGE, Rac1, CCR2, MCP-1). This universal approach addresses the inefficacy of single-pathway targeting by providing broad-spectrum anti-angiogenic activity
Data Source
AI summary
The present disclosure relates to combination the combination, pharmaceutical compositions and kits comprising at least two small molecule inhibitors (SMIs) of respectively at least two proteins of different signaling pathways of retinal disease and methods for treating a retinal disease.